The Effect of ACEI/ARB on the Outcomes of COVID-19 Hospitalized Patients

Considering that there are different reports about the effects of angiotensin II type-I receptor blockers (ARB) and angiotensinconverting enzyme inhibitors (ACEI) on the outcomes of the patients with COVID-19, we aimed to conduct this retrospective study on 138 hypertensive patients (81 ACEI/ARB users) to assess the patients’ outcomes by comparing ACEI/ARB and non-ACEI/ARB users. Multivariate adjusted cox regressionmodel, by considering the effect of other variables, demonstrated that increased age (HR = 1.04, 95% CI = 1.01 -1.07, P =0.003) and non- ACEI/ARB users (HR = 2.12 95% CI = 1.12 - 4.13, P = 0.021) were associated with increased risk of in-hospital mortality in about one week follow-up. In conclusion, we found that in-hospital mortality was lower in ACEI/ARB users, showing the positive effect of these treatments on patients’ outcomes.